• Alnylam Pharmaceuticals has reported new clinical and real world data on its RNAi therapy vutrisiran in ATTR-CM, highlighting durable benefits in quality of life and reductions in advanced disease progression and mortality.
• The company has also shared pooled Phase 2 safety data for zilebesiran that supports its move into a global Phase 3 trial in hypertension and cardiovascular risk reduction.

For investors tracking NasdaqGS:ALNY, this update centers on the company’s core RNAi franchise and its reach into cardiomyopathy and broader cardiovascular disease. Alnylam shares last closed at $330.87, and the stock is up 24.0% over the past year and 135.2% over the past 5 years, reflecting meaningful long term value creation over that period.

The new vutrisiran and zilebesiran data may influence how you think about Alnylam’s product depth in ATTR-CM and its push into hypertension, a large cardiovascular market. As the company advances zilebesiran into Phase 3 and builds the evidence base for vutrisiran, investors may focus more closely on clinical outcomes, regulatory milestones, and competitive responses that could shape Alnylam’s future opportunities.

Stay updated on the most important news stories for Alnylam Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Alnylam Pharmaceuticals.

Quick Assessment

• ✅ Price vs Analyst Target: At US$330.87 vs a consensus target of US$449.32, the shares sit about 26% below where analysts collectively mark fair value.
• ✅ Simply Wall St Valuation: The stock is flagged as undervalued, trading 46.1% below one estimate of fair value.
• ✅ Recent Momentum: A 30 day return of 1.8% suggests modest positive short term sentiment.

There is only one way to know the right time to buy, sell or hold Alnylam Pharmaceuticals. Head to the Simply Wall St company report for the latest analysis of Alnylam Pharmaceuticals's Fair Value.

Key Considerations

• 📊 Vutrisiran data in ATTR-CM and zilebesiran safety in hypertension both strengthen the RNAi story across cardiomyopathy and broader cardiovascular risk.
• 📊 Keep an eye on Phase 3 progress, regulatory interactions, and how a 139.9x P/E compares with future earnings expectations.
• ⚠️ The flagged risk of significant insider selling over the past 3 months is worth watching alongside any major data or price moves.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Alnylam Pharmaceuticals analysis. Alternatively, you can visit the community page for Alnylam Pharmaceuticals to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.